secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2026-08-31T20:18:04+00:00
Accession:  0000939767-26-000104
Event type: litigation
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Federal Circuit affirms Exelixis patents; generic competitor blocked until Jan 15, 2030
--------------------------------------------------------------------------------

- Court of Appeals affirmed validity of U.S. Patent Nos. 11,091,439, 11,091,440, 11,098,015.
- FDA approval of MSN's ANDA effective no earlier than Jan 15, 2030, subject to appeals and exclusivity.
- MSN's appeal on patent 11,298,349 dismissed as moot; that ruling vacated.
- Separate litigation on patent 12,128,039 (expires Feb 2032) with trial set for Nov 2026.
- Outcome protects Exelixis from generic competition until at least 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000104/0000939767-26-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976726000104/exel-20260831.htm
  HTML page:      https://secwatch.observer/filing/0000939767-26-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer